aspirin has been researched along with tirofiban in 150 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (8.00) | 18.2507 |
| 2000's | 82 (54.67) | 29.6817 |
| 2010's | 40 (26.67) | 24.3611 |
| 2020's | 16 (10.67) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ambrose, J; Cohen, M; Fitzpatrick, V; Herrmann, HC; Kereiakes, DJ; Kleiman, NS; McKee, DB; Palabrica, T; Rodriguez, S; Sax, FL; Sutton, JM; Weaver, WD | 1 |
| Badimon, JJ; Chesebro, JH | 1 |
| Aoki, T; Honda, S; Okubo, M; Seki, J; Senzaki, K; Takahashi, F; Takasugi, H; Tanaka, A; Tomiyama, Y | 1 |
| Liron, M | 1 |
| Al-Mousa, EN; Arshad, MN; Campsey, M; Gandhi, R; Gibson, CM; Marble, SJ; Mattson, S; Mesley, R; Moynihan, JL; Murphy, S; Ryan, KA; Swanson, J | 1 |
| Kaluza, G; Kleiman, NS; Mazur, W | 1 |
| Harrington, RA | 1 |
| Juran, NB | 1 |
| Mohammad, SF; Solen, KA; Sukavaneshvar, S | 1 |
| Chadow, HL; Giarraffa, L; Gunsburg, MY; Hauptman, RE; Rafii, SE; Strom, JA; VanAuker, M | 1 |
| Alexander, J; Barr, E; Ghannam, AF; Pharand, C; Sax, FL; Snapinn, S; Théroux, P | 1 |
| Agustí, A; Araujo, R | 1 |
| Droullé, C; Garnotel, R; Hézard, N; Metz, D; Nguyen, P; Potron, G | 1 |
| Bassand, JP | 1 |
| Auer, J; Berent, R; Eber, B; Maurer, E; Mayr, H; Weber, T | 1 |
| Schrör, K | 1 |
| Nurden, P | 1 |
| Braunwald, E; Cannon, CP; DeLucca, PT; Demopoulos, LA; DiBattiste, PM; Frey, MJ; Gibson, CM; Lakkis, N; Neumann, FJ; Robertson, DH; Vicari, R; Weintraub, WS | 1 |
| Ito, H; Kimura, Y; Ozeki, Y; Sudo, T | 1 |
| Lassila, R | 1 |
| Campbell, P | 1 |
| Alston, SM; Goodman, PD; Hall, MW; Solen, KA | 1 |
| Henry, RG; Little, JW; McIntosh, BA; Miller, CS | 1 |
| Bonz, AW; Ertl, G; Harre, K; Held, S; Kochsiek, N; Lengenfelder, B; Meesmann, M; Neyses, L; Schanzenbächer, P; Strotmann, J; Turschner, O; Voelker, W; Wacker, C; Waller, C | 1 |
| Bigonzi, F; Borzak, S; Cohen, M; Frey, MJ; Harris, K; Lis, J; Mukherjee, R; Senatore, F; Théroux, P; Van Mieghem, W; White, HD | 1 |
| Barbera, FA; Dorsam, RT; Feuerstein, GZ; Friedman, SM; Gibbs, S; Lauver, A; Savion, N; Varon, D; Wang, H; Wang, X | 1 |
| Brinkman, WT; Chaikof, EL; Najibi, S; Terramani, TT | 1 |
| Alves, VL; Nannizzi-Alaimo, L; Phillips, DR | 1 |
| Tsakiris, DA | 1 |
| Goto, S | 1 |
| Junghans, U; Siebler, M | 1 |
| Böhm, M; Fries, R | 1 |
| Bowbrick, VA; Mikhailidis, DP; Stansby, G | 1 |
| Blazicek, H; Domanovits, H; Galehr, E; Jilma, B; Jilma-Stohlawetz, P; Mayr, F; Reiter, RA | 1 |
| Cakmak, M; Cam, N; Okmen, E; Tartan, Z | 1 |
| Bestehorn, HP; Bollwein, H; Dirschinger, J; Kastrati, A; Mehilli, J; Neumann, FJ; Pogatsa-Murray, G; Schmitt, C; Schömig, A; Seyfarth, M | 1 |
| Berger, PB; Bhatt, DL; Chan, AW; DiBattiste, PM; Moliterno, DJ; Sapp, SK; Stone, GW; Topol, EJ; Wolski, K; Yakubov, SL | 1 |
| Campbell, ME; Tcheng, JE | 1 |
| Bigonzi, F; Cohen, M; Danchin, N; Gensini, GF; Gurfinkel, EP; Hecquet, C; Huber, K; Krzeminska-Pakula, M; Maritz, F; Santopinto, J; Timerman, A; Vittori, L; White, HD | 1 |
| Besta, F; Gawaz, M; Massberg, S; Mueller, I; Thomas, P | 1 |
| Aquilina, M; Branzi, A; Gaiba, W; Marrozzini, C; Marzocchi, A; Neri, S; Ortolani, P; Palmerini, T | 1 |
| Adgey, AA; Manoharan, G | 1 |
| Atar, S; Birnbaum, Y; Chen, M; Kobal, S; Luo, H; Miyamoto, T; Neuman, Y; Siegel, RJ | 1 |
| Antman, EM; Braunwald, E; Cannon, CP; Demopoulos, LA; DiBattiste, PM; Giugliano, RP; McCabe, CH; Morrow, DA; Murphy, SA; Sabatine, MS; Weintraub, WS | 1 |
| Bolton, ED; Braunstein, JB; Chiles, KA; Faraday, N; Gerstenblith, G; Heldman, AW; Schulman, SP | 1 |
| Haerten, K; Krabbe, C; Raiber, M | 1 |
| Abdel-Aty, H; Al-Saadi, N; Friedrich, MG; Messroghli, DR; Schulz-Menger, J; Taylor, AJ | 1 |
| Ardissino, D; Bilheimer, DW; Blazing, MA; Braunwald, E; Califf, RM; de Lemos, JA; DiBattiste, PM; Fox, KA; Gardner, LH; Hasselblad, V; Lewis, EF; Palmisano, J; Pfeffer, MA; Ramsey, KE; Snapinn, SM; Verheugt, FW; White, HD | 1 |
| Brener, SJ; Lincoff, AM; Moliterno, DJ; Steinhubl, SR; Topol, EJ; Wolski, KE | 1 |
| Domanovits, H; Frossard, M; Fuchs, I; Hsieh, K; Jilma, B; Laggner, AN; Leitner, JM; Losert, H; Schreiber, W; Vlcek, M | 1 |
| Angioli, P; Baldassarre, S; Bolognese, L; Burali, A; Ducci, K; Falsini, G; Liistro, F | 1 |
| Ito, H; Miyakoda, G; Mori, T | 1 |
| Bilheimer, DW; Blazing, MA; Brady, WE; Braunwald, E; Califf, RM; de Lemos, JA; Fox, KA; Lewis, EF; Palmisano, J; Pfeffer, M; Ramsey, KE; White, HD; Wiviott, SD | 1 |
| Hamm, CW; Heeschen, C; Lantelme, NH; Mitrovic, V; White, HD | 1 |
| Cannon, CP; Dibattiste, PM; Gibson, CM; Karha, J; Murphy, SA | 1 |
| Erkoc, R; Eryonucu, B; Tuncer, M | 1 |
| Baum, H; Braun, S; Dibra, A; Dirschinger, J; Hadamitzky, M; Kastrati, A; Mehilli, J; Schömig, A; Schühlen, H | 1 |
| Bhatt, DL; Duffy, B | 1 |
| Buckland, RJ; Holgate, CE; Judge, HM; Storey, RF | 1 |
| Gao, RL; Jing, ZC; Meng, L; Wang, YW; Wu, YJ; Yang, WX; Yang, YJ; You, SJ; Zhao, JL | 1 |
| Kecskés, M; Losonczy, H; Nagy, A; Pótó, L; Szabó, C; Tóth, O | 1 |
| Barutcu, I; Boztosun, B; Gunes, Y; Kirma, C | 1 |
| Dambrink, JH; de Boer, MJ; Gosselink, M; Hoorntje, JC; Miedema, K; Ottervanger, JP; Rasoul, S; Suryapranata, H; van 't Hof, AW; Zijlstra, F | 1 |
| Jennings, LK | 1 |
| Radke, PW; Schunkert, H | 1 |
| Fontana, P | 1 |
| Fallon, AM; Hanson, SR; Marzec, UM; Yoganathan, AP | 1 |
| Blancas Gómez-Casero, R; Chana García, M; González Manzanares, JL; López Matamala, B; Martín Delgado, C; Martínez Díaz, C; Nevado Losada, E; Serrano Castañeda, J; Yáñez Parareda, E | 1 |
| Augoustides, JG | 1 |
| Chung, TL; Holton, LH; Pumplin, DW; Rodriguez, ED; Silverman, RP; Taylor, JA | 1 |
| Boden, WE; Hoekstra, J; Miller, CD | 1 |
| Fan, WZ; Fu, XH; Geng, W; Gu, XS; Hao, GZ; Hao, QQ; Jia, XW; Jiang, YF; Li, SQ; Wu, WL | 1 |
| Allegretto, N; Barbera, F; Bird, JE; Giancarli, MR; Ogletree, ML; Schumacher, WA; Seiffert, D; Wong, P | 1 |
| Barlocco, F; D'Urbano, M; De Servi, S; Fetiveau, R; Poli, A; Savonitto, S; Vandoni, P | 1 |
| Angiolillo, DJ; Campo, G; Colangelo, S; de Cesare, N; Ferrari, F; Ferrari, R; Furgieri, A; Hamon, M; Kubbajeh, M; Meliga, E; Parrinello, G; Percoco, G; Repetto, A; Sabatè, M; Tumscitz, C; Valgimigli, M; Vranckx, P | 1 |
| Becker, RC; Cannon, CP; Goodman, SG; Gutterman, D; Guyatt, GH; Harrington, RA; Lincoff, AM; Popma, JJ; Steg, G | 1 |
| Acar, G; Nacar, AB; Sökmen, G; Tuncer, C | 1 |
| Dembo, L; Lovett, M; O'Driscoll, G; Thomas, MD; Wood, C | 1 |
| Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH | 1 |
| Chen, L; Gai, LY; Jin, J; Li, HY; Li, RB; Lin, L; Liu, CX; Liu, HB; Ren, YH; Wang, CY; Wang, HY; Wang, Y; Xin, YH; Xu, XL; Yang, TS | 1 |
| Chen, SW; Huang, LP; Huang, WG; Wang, LX; Wei, JR; Wu, TG; Zhao, J; Zhao, Q | 1 |
| Biondi-Zoccai, G; Lotrionte, M; Sheiban, I | 1 |
| Giannitsis, E; Ivandic, BT; Katus, HA; Keck, F; Kurz, K; Lehrke, S; Staritz, P | 1 |
| Ottervanger, JP; Remijn, JA; Slingerland, RJ; Smit, JJ; van 't Hof, AW; van Oeveren, W; Zijlstra, F | 1 |
| Bildirici, U; Celikyurt, U; Ural, E | 1 |
| Angiolillo, DJ; Brugaletta, S; Campo, G; Colangelo, S; de Cesare, N; Ferrari, R; Furgieri, A; Hamon, M; Meliga, E; Parrinello, G; Percoco, G; Repetto, A; Sabatè, M; Valgimigli, M; Vranckx, P | 1 |
| De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW | 1 |
| Ding, FH; DU, R; Hu, J; Shen, J; Shen, WF; Zhang, Q; Zhang, RY; Zhang, X; Zhao, LP | 1 |
| Boiti, C; Borutti, G; Cazzaniga, M; Falaschi, F; Maestroni, A; Mandelli, C; Manganaro, D; Monzani, V; Rossi, P; Torgano, G; Zecca, B; Zilioli, E | 1 |
| Campo, G; Cangiano, E; Cavazza, C; Ferrari, R; Fileti, L; Frangione, A; Luccarelli, S; Valgimigli, M | 1 |
| Dai, K; Li, S; Liu, G; Shi, Q; Wang, Y; Wang, Z; Zhang, W | 1 |
| Doraiswamy, VA | 1 |
| Tebaldi, M; Valgimigli, M | 1 |
| Basak, S; Bhattacharya, R; Das Baksi, S; Dutta, D; Gangopadhyay, S; Pani, A; Sarkar, RN | 1 |
| Dill, T; Hamm, C; Heestermans, T; Ottervanger, JP; Slingerland, R; Smit, JJ; ten Berg, J; van 't Hof, AW; van Werkum, JW | 1 |
| Brugaletta, S; Campo, G; Colangelo, S; de Cesare, N; Ferrari, R; Fileti, L; Furgieri, A; Meliga, E; Russo, F; Valgimigli, M | 1 |
| Handa, M; Ikeda, Y; Okamura, Y; Watanabe, N; Yoshida, H | 1 |
| Boes, L; Bonz, AW; Ertl, G; Lengenfelder, B; Stoerk, S; Strotmann, J; Voelker, W | 1 |
| Moliterno, DJ | 1 |
| Dambrink, JH; de Boer, MJ; Gosselink, AT; Hamm, C; Heestermans, T; Koopmans, P; Mosterd, A; ten Berg, JM; van 't Hof, AW; van Houwelingen, G; van Werkum, JW; Zijlstra, F | 1 |
| Biondi Zoccai, G; Bollati, M; Giraudi, E; Millesimo, G; Moretti, C; Omedè, P; Sciuto, F; Sheiban, I | 1 |
| Chen, R; Gao, L; Gao, W; Li, LJ; Lu, CY; Tian, JW; Xue, Q; Zhai, JY; Zhang, YX; Zhou, SH | 1 |
| Breet, NJ; Dambrink, JH; Gosselink, AT; Hamm, C; Hermanides, RS; Ottervanger, JP; ten Berg, JM; van 't Hof, AW; van Houwelingen, KG; van Werkum, JW | 1 |
| Dambrink, JH; Gosselink, AT; Hamm, C; Hermanides, RS; Ottervanger, JP; Stella, PR; ten Berg, JM; van 't Hof, AW; van Houwelingen, G | 1 |
| Arystanova, AZh; Balli, M; Batyraliev, TA; Fettser, DV; Kagliian, KÉ; Samko, AN; Serchelik, A; Sidorenko, BA; Tekin, K; Turkmen, S | 1 |
| Ballesteros Ortega, D; Blancas Gómez-Casero, R; Castro Gallego, O; Chana García, M; Estébanez Montiel, B; López Matamala, B; Marina Martínez, L; Martín Parra, C; Martínez González, O; Prieto Valderrey, F; Quintana Díaz, M; Vigil Escribano, D | 1 |
| Gao, YX; Li, L; Li, Y; Sun, TW; Yu, XZ; Yuan, YQ; Zhao, XY | 1 |
| Liu, XH; Qu, Y; Shen, H; Xia, JG | 1 |
| Abraha, I; Ciccone, A; Cozzolino, F; Motto, C; Santilli, I | 1 |
| Angiolillo, DJ; Antonelli, M; Biglioli, F; Boni, L; Bovenzi, F; Bozzani, A; Bramucci, E; Buffoli, F; Capodanno, D; Castiglioni, B; Comel, A; Cremonesi, A; Crescini, C; D'Angelo, F; De Servi, S; Dionigi, G; Droghetti, A; Francetti, L; Gadda, F; Guagliumi, G; Lettieri, C; Lettino, M; Lorini, L; Musumeci, G; Parolari, A; Piccaluga, E; Ravelli, P; Rossini, R; Salvi, L; Savonitto, S; Scarone, P; Setacci, C; Staurenghi, G; Trabattoni, D; Valdatta, L; Visconti, LO | 1 |
| Agostoni, P; Stella, PR; Timmers, L | 1 |
| Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L | 1 |
| Natarajan, D | 1 |
| Barbieri, L; De Luca, G; Marino, P; Schaffer, A; Verdoia, M | 1 |
| Bruder, M; El-Fiki, A; Güresir, E; Konczalla, J; Lescher, S; Schuss, P; Seifert, V; Vatter, H | 1 |
| Chalouhi, N; Daou, B; Hasan, DM; Jabbour, P; Shields, B; Starke, RM | 1 |
| Choi, JH; Chon, MK; Chun, KJ; Han, DC; Han, J; Hwang, J; Hwang, KW; Jeong, YH; Kim, CH; Kim, IS; Kim, JH; Kim, JS; Lee, SH; Lee, SM; Lee, SY; Noh, M; Park, DW; Park, YH; Sohn, CB | 1 |
| Boschetti, E; D'Urbano, M; De Servi, S; Klugmann, S; La Vecchia, C; Lazzari, L; Martina, P; Morici, N; Musumeci, G; Rossini, R; Savonitto, S; Senni, M | 1 |
| Dash, S; Kar, D; Ray, M; Sahrawat, TR; Shahbazi, S; Singh, S | 1 |
| Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD | 1 |
| Chen, Q; Geng, G; Han, W; Hao, Y; Hao, Z; Jia, K; Liu, H; Liu, L; Liu, Y; Wang, D; Zhou, Y | 1 |
| Chourdakis, E; Hahalis, G; Koniari, I; Kounis, NG; Patsouras, N; Roumeliotis, A; Soufras, G; Tsigkas, G | 1 |
| Chen, WH; Lin, DL; Lin, XH; Wu, YM; Yi, TY; Zhang, MF | 1 |
| Chae, IH; Cho, YS; Lee, W; Park, JJ; Suh, JW; Yoon, CH; Youn, TJ | 1 |
| Berberat, J; Diepers, M; Gruber, P; Hlavica, M; Kahles, T; Nedeltchev, K; Remonda, L; Victor Ineichen, B | 1 |
| Banerjee, S; Baskar, A; Chauhan, S; Cui, Z; Dargham, BB; Sum-Ping, J; Tejani, I; Weideman, RA | 1 |
| Busuttil-Crellin, X; Cowley, J; Ignjatovic, V; Linden, M; McCafferty, C; Monagle, P | 1 |
| Amos, D; Brieger, D; Elder, A; Lowe, HC; McGhie, D | 1 |
| Forleo, GB; Radovanovic, D; Santus, P; Viecca, M | 1 |
| Bärnthaler, T; Buschmann, E; Heinemann, A; Mahla, E; Prüller, F; Schuligoi, R; Toth, GG | 1 |
| Chen, M; Dai, X; Deng, X; Fu, S; Gong, Q; He, W; Huang, L; Li, C; Luo, Q; Qiu, T; Wang, J; Wang, M; Xiao, H | 1 |
| Chen, Y; Fu, B; Li, P | 1 |
| Chen, Y; Wang, B; Wang, W; Wei, S | 1 |
| Chang, W; Li, L; Lin, F; Liu, H; Yin, J; Zhang, H; Zhao, Y | 1 |
| Chen, C; Hu, W; Liu, D; Liu, J; Liu, T; Luo, W; Song, J; Tao, C; Yuan, X; Zhang, C; Zhu, Y | 1 |
| Li, F; Peng, R | 1 |
| Beaujeux, R; Chibbaro, S; Gheoca, R; Hasiu, A; Mangin, PH; Mihoc, D; Pop, R; Quenardelle, V; Severac, F; Simu, M; Tudor, R; Wolff, V | 1 |
| Emani, SM; Piekarski, BL; Rogers, J; Thiagarajan, R; Zurakowski, D | 1 |
| Hu, J; Huang, J; Kong, W; Li, F; Li, L; Liu, S; Luo, W; Nogueira, RG; Qiu, Z; Sang, H; Saver, JL; Song, J; Tian, Y; Yang, J; Yang, Q; Zi, W | 1 |
| Aguilar-Pérez, M; Ainz-Gómez, L; Amaya Pascasio, L; Baena-Palomino, P; Bravo Rey, I; Cabezas-Rodríguez, JA; Castellanos Rodrigo, MDM; de Albóniga-Chindurza, A; Delgado-Acosta, F; Díaz Pérez, J; Escudero-Martínez, I; Fernandez Prudencio, L; Freijo Guerrero, MDM; Gamero-García, MÁ; González Díaz, E; González García, A; Hidalgo, C; Jiménez Jorge, S; Jiménez-Gómez, E; Medina-Rodríguez, M; Moniche, F; Montaner, J; Morales Caba, L; Mosteiro, S; Ortega-Quintanilla, J; Oteros Fernández, R; Pardo-Galiana, B; Ramirez Moreno, JM; Rosso Fernández, C; Sanz-Fernandez, G; Vielba-Gomez, I; Zamora, A; Zapata-Arriaza, E | 1 |
| Chen, D; Gao, X; He, C; Huan, X; Huang, X; Li, Y; Liu, L; Zhang, T | 1 |
| Lin, ZH; Zhang, ZM; Zhu, GL | 1 |
| Cai, T; Cao, M; Chen, X; Chen, Z; Cheng, D; Geng, W; Guo, C; He, P; He, W; Hu, J; Huang, F; Huang, J; Huang, W; Huang, X; Kong, W; Li, B; Li, F; Li, H; Li, L; Li, Z; Liang, H; Liu, C; Liu, J; Liu, S; Liu, W; Liu, Z; Luo, J; Miao, J; Mu, J; Nogueira, RG; Peng, Y; Qiu, Z; Saver, JL; Shi, Q; Shi, Z; Song, J; Tan, X; Tang, M; Tang, Y; Tian, Y; Wan, Y; Wang, D; Wang, M; Wang, P; Wu, Y; Xie, S; Xie, W; Yang, D; Yang, J; Yang, Q; Yang, S; Yao, L; Yu, Y; Yu, Z; Yue, C; Zhang, B; Zhao, H; Zheng, J; Zi, W | 1 |
23 review(s) available for aspirin and tirofiban
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Cardiology; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Embolism; Eptifibatide; Female; Fibrinolytic Agents; Follow-Up Studies; Forecasting; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk; Stents; Structure-Activity Relationship; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Antiplatelet therapy for treatment of acute coronary syndromes.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine; Vascular Patency | 1999 |
Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes.
Topics: Acute Disease; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |
Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Catheterization, Peripheral; Coronary Disease; Coronary Thrombosis; Eptifibatide; Femoral Artery; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Revascularization; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |
[Platelet-leukocyte interactions in coronary heart disease: pathophysiology, clinical relevance, pharmacological modulation].
Topics: Abciximab; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood Platelets; CD18 Antigens; Chemotaxis, Leukocyte; Coronary Artery Bypass; Coronary Disease; Cytokines; Fibrinogen; Heparin; Humans; Immunoglobulin Fab Fragments; Leukocytes; Ligands; Macrophage-1 Antigen; Membrane Glycoproteins; Models, Biological; Myocardial Infarction; Neutrophils; P-Selectin; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombospondins; Tirofiban; Tyrosine | 2000 |
Low-molecular-weight heparin and other antithrombotic agents in the setting of a fast-track revascularization in unstable coronary artery disease.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clinical Trials as Topic; Combined Modality Therapy; Diabetes Complications; Drug Therapy, Combination; Eptifibatide; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Hirudin Therapy; Hirudins; Humans; Immunoglobulin Fab Fragments; Myocardial Revascularization; Oligosaccharides; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Randomized Controlled Trials as Topic; Recombinant Proteins; Risk Factors; Thrombocytopenia; Thrombosis; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
[Acute coronary syndromes: an update. I. Pathogenesis and drug therapy].
Topics: Acute Disease; Administration, Oral; Adrenergic beta-Antagonists; Angina, Unstable; Anticoagulants; Aspirin; Calcium Channel Blockers; Clinical Trials as Topic; Clopidogrel; Electrocardiography; Fibrinolytic Agents; Humans; Multicenter Studies as Topic; Myocardial Infarction; Nitrates; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Syndrome; Terminology as Topic; Ticlopidine; Tirofiban; Tyrosine | 2001 |
[GPIIb-IIIa inhibitors].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Antithrombotic agents: implications in dentistry.
Topics: Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Dental Care; Drug Interactions; Embolism; Fibrinolytic Agents; Hemostasis; Heparin; Heparin, Low-Molecular-Weight; Humans; Oral Hemorrhage; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Ticlopidine; Tirofiban; Tyrosine; Venous Thrombosis; Warfarin | 2002 |
Platelets: is aspirin sufficient or must we know how to pronounce abciximab?
Topics: Abciximab; Antibodies, Monoclonal; Arteriosclerosis; Aspirin; Blood Platelets; Clopidogrel; Endarterectomy, Carotid; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Ticlopidine; Tirofiban; Tyrosine | 2002 |
[GP IIb/IIIa receptor prevention medicine].
Topics: Abciximab; Animals; Antibodies, Monoclonal; Aspirin; Clinical Trials as Topic; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombolytic Therapy; Tirofiban; Tyrosine | 2003 |
[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].
Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Anticholesteremic Agents; Arrhythmias, Cardiac; Aspirin; Atorvastatin; Clopidogrel; Defibrillators, Implantable; Double-Blind Method; Fibrinolytic Agents; Heart Failure; Heart Septal Defects, Atrial; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Myocardial Infarction; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Regeneration; Risk Factors; Syndrome; Ticlopidine; Time Factors; Tirofiban; Tyrosine | 2003 |
Current management of unstable angina: lessons from the TACTICS-TIMI 18 trial.
Topics: Angina, Unstable; Angioplasty, Balloon; Aspirin; Dalteparin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Myocardial Ischemia; Randomized Controlled Trials as Topic; Risk Assessment; Thrombolytic Therapy; Tirofiban; Tyrosine | 2002 |
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Comorbidity; Coronary Restenosis; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Peptide Fragments; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Stents; Thrombophilia; Ticlopidine; Tirofiban; Tyrosine | 2004 |
Antiplatelet agents in patients undergoing percutaneous coronary intervention: how many and how much?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clinical Trials as Topic; Clopidogrel; Eptifibatide; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Recombinant Proteins; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2005 |
[Antithrombotic treatment of acute coronary syndromes without ST-segment elevation].
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Clopidogrel; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Syndrome; Ticlopidine; Tirofiban; Tyrosine | 2006 |
[Update on antithrombotic treatments in arterial diseases].
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Arteriosclerosis; Aspirin; Dipyridamole; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Pyridines; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Clopidogrel; Electrocardiography; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Ticlopidine; Tirofiban; Tyrosine | 2008 |
Safety evaluation of tirofiban.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Double-Blind Method; Drug Resistance; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Incidence; Multicenter Studies as Topic; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombocytopenia; Ticlopidine; Tirofiban; Tyrosine | 2010 |
Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Brain Ischemia; Humans; Immunoglobulin Fab Fragments; Intracranial Hemorrhages; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Stroke; Tirofiban; Tyrosine | 2014 |
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin | 2014 |
51 trial(s) available for aspirin and tirofiban
| Article | Year |
|---|---|
Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Tyrosine | 1996 |
Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Tirofiban; Tyrosine | 1998 |
A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heparin; Humans; Incidence; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Tirofiban; Tyrosine | 1998 |
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Cardiology; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Embolism; Eptifibatide; Female; Fibrinolytic Agents; Follow-Up Studies; Forecasting; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk; Stents; Structure-Activity Relationship; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Uns
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Diabetes Complications; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heparin; Humans; Infusions, Intravenous; Likelihood Functions; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Elective Surgical Procedures; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Premedication; Stents; Ticlopidine; Tirofiban; Troponin T; Tyrosine | 2002 |
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Infusions, Intravenous; Male; Middle Aged; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Cerebral microembolism is blocked by tirofiban, a selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Carotid Artery Diseases; Clopidogrel; Female; Humans; Infusions, Intravenous; Intracranial Embolism; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine; Ultrasonography, Doppler, Transcranial | 2003 |
Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin.
Topics: Abciximab; Adenosine Diphosphate; Adult; Antibodies, Monoclonal; Aspirin; Collagen; Cross-Over Studies; Deamino Arginine Vasopressin; Dose-Response Relationship, Drug; Double-Blind Method; Epinephrine; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2003 |
Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Female; Fibrinolytic Agents; Heart Conduction System; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Research Design; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial.
Topics: Aged; Angina Pectoris; Aspirin; Catheterization; Clopidogrel; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Revascularization; Platelet Aggregation Inhibitors; Preoperative Care; Risk; Stents; Ticlopidine; Tirofiban; Treatment Outcome; Troponin T; Tyrosine | 2003 |
Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immunoglobulin Fab Fragments; Louisiana; Male; Middle Aged; Minnesota; Myocardial Infarction; New York City; Ohio; Pennsylvania; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Premedication; Severity of Illness Index; Stents; Survival Analysis; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial
Topics: Administration, Oral; Aspirin; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Incidence; Injections, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Time Factors; Tirofiban; Tyrosine | 2003 |
Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Endothelium, Vascular; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Stents; Ticlopidine; Tirofiban; Tyrosine | 2003 |
Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes.
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Arachidonic Acid; Aspirin; Blood Platelets; C-Reactive Protein; Cell Aggregation; Drug Resistance; Eptifibatide; Female; Heparin; Humans; Leukocytes; Male; Middle Aged; Monocytes; Multivariate Analysis; Myocardial Infarction; Myocardial Ischemia; Neutrophils; Patient Selection; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Receptors, Thrombin; Recurrence; ROC Curve; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2004 |
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Topics: Aged; Angina Pectoris; Aspirin; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial.
Topics: Aspirin; Coronary Disease; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes.
Topics: Acute Disease; Anticoagulants; Aspirin; Biomarkers; C-Reactive Protein; Drug Therapy, Combination; Follow-Up Studies; Heparin; Humans; Incidence; Myocardial Infarction; Myocardial Ischemia; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Peptide Fragments; Predictive Value of Tests; Risk; Risk Assessment; Syndrome; Tirofiban; Troponin T; Tyrosine | 2004 |
A comparison of dual vs. triple antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndrome: results of the ELISA-2 trial.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Drug Combinations; Enzymes; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
[Absence of benefit with triple antiaggregation in acute non persistent ST segment elevation myocardial infarction in patients not subjected to early interventionism].
Topics: Aged; Aspirin; Clopidogrel; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine; Tirofiban; Tyrosine | 2007 |
Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Tyrosine; Vasodilation | 2008 |
Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Drug Resistance; Europe; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Research Design; Ticlopidine; Tirofiban; Treatment Outcome; Troponin I; Troponin T; Tyrosine | 2008 |
Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Vessels; Drug Administration Routes; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Tirofiban; Tyrosine | 2008 |
Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Necrosis; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Iron-induced platelet aggregation measurement: a novel method to measure platelet function in stenting for ST segment elevation myocardial infarction.
Topics: Aged; Aspirin; Clopidogrel; Feasibility Studies; Female; Humans; Iron; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Reproducibility of Results; Stainless Steel; Stents; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug Resistance; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2009 |
Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Emergency Medical Services; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Stents; Thrombolytic Therapy; Ticlopidine; Tirofiban; Tyrosine | 2009 |
Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Disability Evaluation; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Fibrinolytic Agents; Hospital Mortality; Humans; Intracranial Hemorrhages; Italy; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recovery of Function; Stroke; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Drug Resistance; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Tyrosine | 2010 |
Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: an East Indian perspective.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Emergency Service, Hospital; Enoxaparin; Female; Follow-Up Studies; Humans; India; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Reference Values; Severity of Illness Index; Survival Rate; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) tr
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Elective Surgical Procedures; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Prospective Studies; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
Long-term reduction of mortality in the 4-year follow up of tirofiban therapy in elective percutaneous coronary interventions (TOPSTAR) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Survival Rate; Ticlopidine; Tirofiban; Treatment Outcome; Troponin; Tyrosine | 2011 |
A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab wi
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; United States | 2011 |
Higher efficacy of pre-hospital tirofiban with longer pre-treatment time to primary PCI: protection for the negative impact of time delay.
Topics: Aged; Ambulances; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Emergency Medical Services; Female; Fibrinolytic Agents; Health Services Accessibility; Heparin; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Netherlands; Outcome and Process Assessment, Health Care; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2011 |
[Tirofiban improved the prognosis of senior acute coronary syndrome patients received percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Ticlopidine; Tirofiban; Tyrosine | 2011 |
The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Emergency Medical Services; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Prospective Studies; Severity of Illness Index; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Vascular Patency | 2012 |
Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Electrocardiography; Emergency Medical Services; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prevalence; Retrospective Studies; Risk Factors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2012 |
[Prevention of non-acute stent thrombosis after drug-eluting stent implantation].
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine; Tirofiban; Tyrosine; Warfarin | 2013 |
Short-term follow-up of tirofiban as alternative therapy for urgent surgery patients with an implanted coronary drug-eluting stent after ST-elevation myocardial infarction.
Topics: Aged; Aspirin; China; Clopidogrel; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prospective Studies; Risk Factors; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Republic of Korea; Ticagrelor; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Tirofiban; Tyrosine | 2016 |
Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Safety; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2017 |
Another Endovascular Therapy Strategy for Acute Tandem Occlusion: Protect-Expand-Aspiration-Revascularization-Stent (PEARS) Technique.
Topics: Acute Disease; Aged; Aspirin; Carotid Artery Thrombosis; Carotid Artery, Internal; Cerebral Revascularization; Clopidogrel; Endovascular Procedures; Feasibility Studies; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Severity of Illness Index; Stents; Thrombectomy; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2018 |
Effect of tailored use of tirofiban in patients with Non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: a randomized controlled trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Biomarkers; Clopidogrel; Coronary Angiography; Creatine Kinase, MB Form; Drug Resistance; Female; Humans; Male; Middle Aged; Myocardium; Necrosis; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Seoul; Time Factors; Tirofiban; Treatment Outcome; Troponin I | 2018 |
Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study.
Topics: Aged; Aspirin; Betacoronavirus; Clopidogrel; Compassionate Use Trials; Coronavirus Infections; COVID-19; Female; Fibrin Fibrinogen Degradation Products; Humans; Hypoxia; Male; Middle Aged; Pandemics; Platelet Aggregation Inhibitors; Pneumonia, Viral; Proof of Concept Study; SARS-CoV-2; Thrombophilia; Tirofiban | 2020 |
Tirofiban combined with heparin's effect and safety in the treatment of mild to moderate acute ischemic stroke.
Topics: Adult; Aged; Aspirin; Clopidogrel; Female; Heparin; Humans; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome | 2021 |
RESCUE BT 2, a multicenter, randomized, double-blind, double-dummy trial of intravenous tirofiban in acute ischemic stroke: Study rationale and design.
Topics: Aspirin; Double-Blind Method; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Prospective Studies; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2023 |
Safety and efficacy of tirofiban in acute ischemic stroke due to tandem lesions undergoing mechanical thrombectomy: A multicenter randomized clinical trial (ATILA) protocol.
Topics: Aspirin; Brain Ischemia; Clinical Trials, Phase IV as Topic; Humans; Ischemic Stroke; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Prospective Studies; Randomized Controlled Trials as Topic; Thrombectomy; Thrombosis; Tirofiban; Treatment Outcome | 2023 |
Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion.
Topics: Aspirin; Brain Ischemia; Cerebral Arterial Diseases; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Ischemic Stroke; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome | 2023 |
77 other study(ies) available for aspirin and tirofiban
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1998 |
Difference of (Ca2+)i movements in platelets stimulated by thrombin and TRAP: the involvement of alpha(IIb)beta3-mediated TXA2 synthesis.
Topics: Adenosine Diphosphate; Antibodies, Monoclonal; Apyrase; Aspirin; Blood Platelets; Calcium; Cyclooxygenase Inhibitors; Dipeptides; Fibrinogen; Humans; Ion Transport; Peptide Fragments; Phenylacetates; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Thrombin; Signal Transduction; Sulfonamides; Thrombin; Thromboxane A2; Thromboxane B2; Tirofiban; Tyrosine | 1998 |
Tirofiban in unstable coronary disease.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Research Design; Tirofiban; Tyrosine | 1998 |
Super-aspirins in severe angina.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 1998 |
An in-vitro model to study device-induced thrombosis and embolism: evaluation of the efficacy of tirofiban, aspirin, and dipyridamole.
Topics: Animals; Anticoagulants; Aspirin; Blood Flow Velocity; Cattle; Dipyridamole; Dose-Response Relationship, Drug; Edetic Acid; Embolism; Equipment and Supplies; Equipment Design; Evaluation Studies as Topic; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Scattering, Radiation; Stents; Thrombosis; Tirofiban; Tyrosine | 2000 |
Drip and ship: a new strategy for the treatment of acute coronary syndromes.
Topics: Abciximab; Acute Disease; Adult; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clinical Protocols; Coronary Angiography; Coronary Disease; Electrocardiography; Female; Fibrinolytic Agents; Heparin; Hospitalization; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Nitrates; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
[New antiplatelet agents].
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Dipyridamole; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2000 |
[Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists].
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Atherectomy; Clinical Trials as Topic; Combined Modality Therapy; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Syndrome; Tirofiban; Tyrosine; United States; United States Food and Drug Administration | 2000 |
[Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa inhibitors].
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Platelets; Clopidogrel; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2001 |
Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method.
Topics: Adenosine Diphosphate; Amino Acid Chloromethyl Ketones; Aspirin; Blood Coagulation; Blood Platelets; Cilostazol; Collagen; Dipyridamole; Filtration; Heparin; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Pressure; Tetrazoles; Time Factors; Tirofiban; Tyrosine | 2001 |
[Antithrombotic therapy of unstable angina pectoris].
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Ticlopidine; Tirofiban; Tyrosine | 1998 |
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Hypothermia-induced platelet aggregation in heparinized flowing human blood: identification of a high responder subpopulation.
Topics: Alprostadil; Anemia, Hemolytic, Autoimmune; Aspirin; Blood Cell Count; Citric Acid; Cold Temperature; Edetic Acid; Filtration; Hemorheology; Heparin; Humans; Hypothermia; Light; Models, Biological; Platelet Aggregation; Platelet Aggregation Inhibitors; Pressure; Protamines; Scattering, Radiation; Tirofiban; Tyrosine | 2002 |
Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.
Topics: Abciximab; Alanine; Amidines; Analysis of Variance; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cell Aggregation; Dose-Response Relationship, Drug; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Isoxazoles; Peptides; Platelet Activation; Platelet Adhesiveness; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Rheology; Shear Strength; Temperature; Tirofiban; Tyrosine | 2002 |
Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Platelets; CD40 Ligand; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Kinetics; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2003 |
[New antiaggregants and their importance for the practitioner].
Topics: Abciximab; Administration, Oral; Adult; Anesthesia, Spinal; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Contraindications; Drug Therapy, Combination; Eptifibatide; Female; Fibrinolytic Agents; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pregnancy; Ticlopidine; Tirofiban; Tyrosine | 2003 |
Value of thromboelastography in the assessment of platelet function.
Topics: Adenosine Diphosphate; Aspirin; Humans; Peripheral Vascular Diseases; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Sensitivity and Specificity; Thrombelastography; Tirofiban; Tyrosine | 2003 |
Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Administration Schedule; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Tyrosine | 2003 |
Beta brachytherapy of an old degenerated saphenous vein graft with occlusive in-stent restenosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Beta Particles; Blood Vessel Prosthesis; Brachytherapy; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Female; Fibrinolytic Agents; Graft Occlusion, Vascular; Humans; Myocardial Infarction; Phosphorus Radioisotopes; Reoperation; Saphenous Vein; Stents; Ticlopidine; Tirofiban; Tyrosine | 2003 |
Synergism of aspirin and heparin with a low-frequency non-invasive ultrasound system for augmentation of in-vitro clot lysis.
Topics: Adult; Aspirin; Drug Synergism; Drug Therapy, Combination; Eptifibatide; Heparin; Humans; In Vitro Techniques; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombolytic Therapy; Tirofiban; Tyrosine; Ultrasonic Therapy | 2003 |
Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and th
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Comorbidity; Coronary Disease; Female; Hospitalization; Humans; Life Tables; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Risk Factors; Severity of Illness Index; Stents; Survival Analysis; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
[Efficacy and safety of treatment of acute ischemic stroke with glycoprotein IIb/IIIa receptor blocker in routine clinical practice].
Topics: Adult; Aged; Anticoagulants; Aspirin; Brain; Brain Ischemia; Carotid Arteries; Clopidogrel; Drug Therapy, Combination; Echocardiography, Transesophageal; Eptifibatide; Female; Heparin; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Stroke; Ticlopidine; Tirofiban; Tomography, X-Ray Computed; Tyrosine; Ultrasonography, Doppler | 2004 |
Detection of acutely impaired microvascular reperfusion after infarct angioplasty with magnetic resonance imaging.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Circulation; Female; Heart Ventricles; Heparin; Humans; Immunoglobulin Fab Fragments; Magnetic Resonance Imaging; Male; Microcirculation; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Prospective Studies; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine; Ventricular Function, Left | 2004 |
Platelet function predicts myocardial damage in patients with acute myocardial infarction.
Topics: Abciximab; Adenosine Diphosphate; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cardiovascular Agents; Clopidogrel; Collagen; Comorbidity; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Leukocyte Count; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardium; Necrosis; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Ticlopidine; Tirofiban; Tyrosine; von Willebrand Factor | 2004 |
Elevations in troponin I after percutaneous coronary interventions are associated with abnormal tissue-level perfusion in high-risk patients with non-ST-segment-elevation acute coronary syndromes.
Topics: Abciximab; Acute Disease; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Biomarkers; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Coronary Circulation; Electrocardiography; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Ischemia; Myocardial Reperfusion Injury; Platelet Aggregation Inhibitors; Prospective Studies; Risk; Ticlopidine; Tirofiban; Troponin I; Tyrosine; Ultrasonography | 2004 |
Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation.
Topics: Antibodies, Monoclonal; Aspirin; Blood Platelets; Calcium; Cell Separation; Cilostazol; Collagen; Cyclic AMP; Humans; Leukocytes; Male; P-Selectin; Platelet Activation; Platelet Adhesiveness; Platelet Glycoprotein GPIIb-IIIa Complex; Tetrazoles; Thrombin; Tirofiban; Tyrosine | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Safety; Tirofiban; Tyrosine | 2004 |
Repetitive profound thrombocytopenia after treatment with tirofiban: a case report.
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Administration Schedule; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Thrombocytopenia; Ticlopidine; Tirofiban; Tyrosine | 2004 |
Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting.
Topics: Abciximab; Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Biomarkers; C-Reactive Protein; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Female; Heparin; Humans; Immunoglobulin Fab Fragments; Inflammation; Male; Middle Aged; Postoperative Period; Premedication; Stents; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
Topics: Abciximab; Adenosine Monophosphate; Antibodies, Monoclonal; Aspirin; Blood Platelets; CD40 Ligand; Coagulants; Humans; Immunoglobulin Fab Fragments; Membrane Proteins; Plasminogen Activator Inhibitor 1; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Receptors, Thrombin; Secretory Vesicles; Tirofiban; Tyrosine | 2005 |
Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion.
Topics: Animals; Aspirin; Clopidogrel; Coronary Circulation; Drug Therapy, Combination; Myocardial Infarction; Myocardial Reperfusion; Nitric Oxide; Nitric Oxide Synthase; Platelet Aggregation Inhibitors; Random Allocation; Swine; Swine, Miniature; Ticlopidine; Tirofiban; Tyrosine | 2006 |
In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters.
Topics: Aspirin; Blood Coagulation; Blood Platelets; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Eptifibatide; Factor Xa Inhibitors; Female; Heparin; Humans; Indoles; Male; Partial Thromboplastin Time; Peptides; Platelet Aggregation Inhibitors; Poly(ADP-ribose) Polymerase Inhibitors; Tirofiban; Tissue Plasminogen Activator; Tyrosine | 2006 |
Successful lysis of coronary thrombi by long term warfarin treatment after a failed course of tirofiban infusion.
Topics: Angina Pectoris; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Enoxaparin; Female; Humans; Infusion Pumps; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine; Tirofiban; Treatment Failure; Treatment Outcome; Tyrosine; Warfarin | 2006 |
Thrombin formation in vitro in response to shear-induced activation of platelets.
Topics: Antithrombin III; Aspirin; Biomedical Engineering; Blood Platelets; Heart Valve Prosthesis; Hemorheology; Humans; In Vitro Techniques; Peptide Hydrolases; Platelet Activation; Platelet Aggregation Inhibitors; Stress, Mechanical; Thrombin; Thromboembolism; Tirofiban; Tyrosine; von Willebrand Factor | 2007 |
Perioperative thrombotic risk of coronary artery stents: possible role for intravenous platelet blockade.
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Injections, Intravenous; Perioperative Care; Platelet Aggregation Inhibitors; Postoperative Complications; Risk Factors; Stents; Ticlopidine; Tirofiban; Tyrosine | 2007 |
Prevention of microsurgical anastomotic thrombosis using aspirin, heparin, and the glycoprotein IIb/IIIa inhibitor tirofiban.
Topics: Anastomosis, Surgical; Animals; Anticoagulants; Aspirin; Drug Therapy, Combination; Heparin; Male; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Random Allocation; Rats; Rats, Sprague-Dawley; Thrombosis; Tirofiban; Tyrosine; Vascular Patency | 2007 |
Prediction of the therapeutic index of marketed anti-coagulants and anti-platelet agents by guinea pig models of thrombosis and hemostasis.
Topics: Animals; Anticoagulants; Arginine; Arteriovenous Shunt, Surgical; Aspirin; Bleeding Time; Chlorides; Ferric Compounds; Guinea Pigs; Hemostasis; Male; Pipecolic Acids; Platelet Aggregation Inhibitors; Sulfonamides; Thrombosis; Tirofiban; Tyrosine | 2008 |
Unplanned surgery after drug eluting stent implantation: a strategy for safe temporary withdrawal of dual oral antiplatelet therapy.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Contraindications; Drug Therapy, Combination; Drug-Eluting Stents; Fibrinolytic Agents; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Preoperative Care; Surgical Procedures, Operative; Ticlopidine; Tirofiban; Tyrosine | 2008 |
Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Electrocardiography; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Platelet Aggregation Inhibitors; Polysaccharides; Risk Assessment; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2008 |
Efficient tirofiban infusion resulting in resolution of intracoronary thrombus.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Electrocardiography; Fibrinolytic Agents; Heptanoic Acids; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine; Tirofiban; Tyrosine | 2008 |
Successful treatment of rotary pump thrombus with the glycoprotein IIb/IIIa inhibitor tirofiban.
Topics: Adult; Anticoagulants; Aspirin; Female; Heart-Assist Devices; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tirofiban; Tyrosine; Warfarin | 2008 |
Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Risk Factors; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Ventricular Dysfunction, Right | 2008 |
Evaluation of triple anti-platelet therapy by modified thrombelastography in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Thrombelastography; Ticlopidine; Tirofiban; Tyrosine | 2008 |
Overcoming "resistance" to aspirin and clopidogrel with tirofiban: fact or fiction?
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Ticlopidine; Tirofiban; Tyrosine | 2008 |
Essential thrombocythemia: a case of acute ST-segment elevation myocardial infarction in a young female.
Topics: Adult; Age Factors; Antisickling Agents; Aspirin; Clopidogrel; Coronary Angiography; Female; Fibrinolytic Agents; Heparin; Humans; Hydroxyurea; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombocythemia, Essential; Ticlopidine; Tirofiban; Tissue Plasminogen Activator; Tyrosine | 2009 |
Triple antiplatelet therapy for clopidogrel resistance with stent malapposition: a case report.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Sirolimus; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Mechanism of platelet functional changes and effects of anti-platelet agents on in vivo hemostasis under different gravity conditions.
Topics: Actin Cytoskeleton; Adenosine Diphosphate; Animals; Aspirin; Blood Platelets; Calcium; Chelating Agents; Contractile Proteins; Egtazic Acid; Filamins; Hemostasis; Humans; Hypergravity; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Microfilament Proteins; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Protein Binding; Ristocetin; Thrombosis; Time Factors; Tirofiban; Tyrosine; Weightlessness Simulation | 2010 |
Letter by Doraiswamy regarding article, "Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring
Topics: Anticoagulants; Aspirin; Clopidogrel; Confounding Factors, Epidemiologic; Double-Blind Method; Drug Resistance; Elective Surgical Procedures; Hemorrhage; Heparin; Humans; Myocardial Revascularization; Patient Selection; Platelet Aggregation Inhibitors; Postoperative Complications; Randomized Controlled Trials as Topic; Research Design; Thromboembolism; Ticlopidine; Tirofiban; Tyrosine | 2010 |
Shear-dependent suppression of platelet thrombus formation by phosphodiesterase 3 inhibition requires low levels of concomitant Gs-coupled receptor stimulation.
Topics: Aspirin; Cyclic AMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Dose-Response Relationship, Drug; GTP-Binding Protein alpha Subunits, Gs; Hemostasis; Humans; Ligands; Platelet Aggregation; Quinolines; Ristocetin; Shear Strength; Tirofiban; Tyrosine; Urea; von Willebrand Factor | 2011 |
Dual oral antiplatelet therapy and unplanned surgery: possible role for intravenous platelet glycoprotein receptor inhibitors.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Biliary Tract Surgical Procedures; Cardiovascular Diseases; Cholangitis; Choledocholithiasis; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Humans; Infusions, Intravenous; Male; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2011 |
[Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome].
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Monitoring; Electrocardiography; Female; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Preoperative Care; Retrospective Studies; Survival Analysis; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
[Influence of the combination of antiplatelet agents on the occurrence of early left ventricular insufficiency in patients with acute coronary syndromes without persistent ST-segment elevation].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine; Ventricular Dysfunction, Left | 2014 |
Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies.
Topics: Anesthesiology; Aspirin; Cardiac Surgical Procedures; Cardiology; Clopidogrel; Eptifibatide; Hemorrhage; Humans; Italy; Myocardial Ischemia; Peptides; Perioperative Care; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Societies, Medical; Stents; Surgical Procedures, Operative; Thoracic Surgery; Ticlopidine; Tirofiban; Tyrosine | 2014 |
Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy.
Topics: Absorbable Implants; Adenosine; Adult; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Graft Occlusion, Vascular; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor; Ticlopidine; Tirofiban; Tissue Scaffolds; Tyrosine | 2015 |
Acute thrombosis during left main stenting using tap technique in a patient presenting with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Drug Combinations; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Stents; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2015 |
[Two catheters for one coronary perforation].
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Aspirin; Cardiac Catheterization; Catheters; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dyslipidemias; Femoral Artery; Heart Injuries; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Percutaneous Coronary Intervention; Premedication; Radial Artery; Stents; Tirofiban; Tyrosine | 2015 |
Ventriculostomy-Related Hemorrhage After Treatment of Acutely Ruptured Aneurysms: The Influence of Anticoagulation and Antiplatelet Treatment.
Topics: Acute Disease; Adult; Aged; Aneurysm, Ruptured; Anticoagulants; Aspirin; Cerebral Hemorrhage; Clopidogrel; Endovascular Procedures; Female; Heparin, Low-Molecular-Weight; Humans; Hydrocephalus; Intracranial Aneurysm; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Thromboembolism; Ticlopidine; Tirofiban; Tyrosine; Ventriculostomy | 2015 |
A New Protocol for Anticoagulation With Tirofiban During Flow Diversion.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clinical Protocols; Clopidogrel; Embolization, Therapeutic; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Intracranial Aneurysm; Intracranial Hemorrhages; Intraoperative Care; Male; Middle Aged; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Tirofiban; Tyrosine | 2016 |
Bridge therapy or standard treatment for urgent surgery after coronary stent implantation: Analysis of 314 patients.
Topics: Ambulatory Care; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Stenosis; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Surgical Procedures, Operative; Tirofiban; Tyrosine | 2016 |
Drug Targets for Cardiovascular-Safe Anti-Inflammatory: In Silico Rational Drug Studies.
Topics: Anti-Inflammatory Agents; Aspirin; Binding Sites; Caffeic Acids; Celecoxib; Coumaric Acids; Cyclooxygenase 1; Cyclooxygenase 2; ERG1 Potassium Channel; Eugenol; Heart; Humans; Inflammation; Integrin alpha2; Protein Structure, Tertiary; Tirofiban; Tyrosine | 2016 |
Perioperative Management of Dual Antiplatelet Therapy.
Topics: Aspirin; Elective Surgical Procedures; Hemorrhage; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine; Tirofiban; Tyrosine | 2018 |
Acute administration of tirofiban versus aspirin in emergent carotid artery stenting.
Topics: Aged; Aspirin; Carotid Stenosis; Cerebral Angiography; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Retrospective Studies; Stents; Stroke; Tirofiban; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Intravenous Antiplatelet Therapy Bridging in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Administration, Intravenous; Aged; Aspirin; Cardiac Surgical Procedures; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Time Factors; Tirofiban; Treatment Outcome | 2019 |
Investigation of the in vitro effect of aspirin and tirofiban in children compared to adults.
Topics: Adolescent; Adult; Aspirin; Child; Child, Preschool; Female; Humans; Male; Tirofiban; Young Adult | 2019 |
Life after abciximab; what's next for intracoronary thrombus?
Topics: Abciximab; Aged; Aspirin; Coronary Thrombosis; Heparin; Humans; Male; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Tirofiban | 2020 |
Supplemental Fibrinogen Restores Platelet Inhibitor-Induced Reduction in Thrombus Formation without Altering Platelet Function: An In Vitro Study.
Topics: Aged; Aspirin; Calcium Signaling; Female; Fibrinogen; Hemorheology; Heparin; Hirudins; Humans; In Vitro Techniques; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Thrombosis; Ticagrelor; Tirofiban | 2020 |
2019 novel coronavirus disease with secondary ischemic stroke: two case reports.
Topics: Aspirin; Atorvastatin; Brain Ischemia; COVID-19; Fibrinolytic Agents; Humans; Ischemic Stroke; Male; Middle Aged; Pandemics; SARS-CoV-2; Tirofiban | 2021 |
Late Stent Thrombosis After Drug-Coated Balloon Coronary Angioplasty for In-Stent Restenosis.
Topics: Acute Disease; Adult; Aftercare; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Occlusion; Coronary Restenosis; Cytochrome P-450 CYP2C19; Dual Anti-Platelet Therapy; Female; Fibrinolytic Agents; Humans; Integrin alpha2; Mutation; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Stents; Thrombectomy; Thrombosis; Ticagrelor; Tirofiban; Treatment Outcome | 2021 |
Assessing the Efficacy and Safety of Tirofiban in Combination With Dual-antiplatelet Therapy in Progressive Ischemic Stroke Patients.
Topics: Aged; Aspirin; Clopidogrel; Disability Evaluation; Dual Anti-Platelet Therapy; Female; Functional Status; Hemorrhage; Humans; Infusions, Intravenous; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Recovery of Function; Retrospective Studies; Time Factors; Tirofiban; Treatment Outcome | 2021 |
Association between tirofiban monotherapy and efficacy and safety in acute ischemic stroke.
Topics: Aspirin; China; Clopidogrel; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Ischemic Stroke; Prospective Studies; Tirofiban | 2021 |
The Clinical Efficacy of Tirofiban Combined with Ticagrelor and Aspirin in Treating Acute Myocardial Infarction by Percutaneous Coronary Intervention and Its Effect on Patients' Cardiac Function.
Topics: Aspirin; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Tirofiban; Treatment Outcome | 2022 |
Conservative versus aggressive antiplatelet strategy for emergent carotid stenting during stroke thrombectomy.
Topics: Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Stroke; Thrombectomy; Tirofiban; Treatment Outcome | 2023 |
Exploratory Use of Glycoprotein IIb/IIIa Inhibition in Prevention of Blalock-Taussig Shunt Thrombosis.
Topics: Anticoagulants; Aspirin; Blalock-Taussig Procedure; Cohort Studies; Fibrinolytic Agents; Hemorrhage; Humans; Integrin alpha2; Integrin beta3; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Thrombosis; Tirofiban; Treatment Outcome | 2022 |
Effect of pathological high shear exposure time on platelet activation and aggregation.
Topics: Aspirin; Blood Platelets; Constriction, Pathologic; Fibrinogen; Humans; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticagrelor; Tirofiban; von Willebrand Factor | 2023 |
Tirofiban in the treatment of cancer-associated ischemic stroke.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Stroke; Neoplasms; Retrospective Studies; Stroke; Tirofiban; Treatment Outcome | 2023 |